This study investigates the blood coagulation function in patients with SARS-CoV-2 infection. A total of 94 patients with confirmed SARS-CoV-2 infection were compared with 40 healthy controls. The results showed that antithrombin (AT) levels were significantly lower in SARS-CoV-2 patients compared to controls (p < 0.001). D-dimer, fibrin/fibrinogen degradation products (FDP), and fibrinogen (FIB) levels were significantly higher in SARS-CoV-2 patients than in controls. Additionally, severe SARS-CoV-2 patients had higher D-dimer and FDP levels than mild cases. Prothrombin time activity (PT-act) was lower in SARS-CoV-2 patients, and thrombin time was shorter in critical cases. These findings suggest that coagulation function is significantly deranged in SARS-CoV-2 patients compared to healthy individuals. Monitoring D-dimer and FDP values may help in the early identification of severe cases. The study also found that coagulation parameters were not significantly different between the three subgroups of SARS-CoV-2 patients (ordinary, severe, critical) and controls for APTT, PT, PT-INR, and TT. However, D-dimer and FDP values were significantly higher in severe cases compared to mild cases. The study concludes that blood coagulation in SARS-CoV-2 patients is significantly deranged, with D-dimer, FDP, and FIB values significantly increased and AT levels significantly decreased. These findings support the notion that consumption coagulopathy, especially disseminated intravascular coagulation (DIC), may be common in SARS-CoV-2 patients and may negatively affect the clinical course. Routine monitoring of hemostasis tests may be useful for establishing an accurate therapeutic strategy and preventing disease progression. The study was approved by the Ethics Committee and Institutional Review Board of the Renmin Hospital of Wuhan University.This study investigates the blood coagulation function in patients with SARS-CoV-2 infection. A total of 94 patients with confirmed SARS-CoV-2 infection were compared with 40 healthy controls. The results showed that antithrombin (AT) levels were significantly lower in SARS-CoV-2 patients compared to controls (p < 0.001). D-dimer, fibrin/fibrinogen degradation products (FDP), and fibrinogen (FIB) levels were significantly higher in SARS-CoV-2 patients than in controls. Additionally, severe SARS-CoV-2 patients had higher D-dimer and FDP levels than mild cases. Prothrombin time activity (PT-act) was lower in SARS-CoV-2 patients, and thrombin time was shorter in critical cases. These findings suggest that coagulation function is significantly deranged in SARS-CoV-2 patients compared to healthy individuals. Monitoring D-dimer and FDP values may help in the early identification of severe cases. The study also found that coagulation parameters were not significantly different between the three subgroups of SARS-CoV-2 patients (ordinary, severe, critical) and controls for APTT, PT, PT-INR, and TT. However, D-dimer and FDP values were significantly higher in severe cases compared to mild cases. The study concludes that blood coagulation in SARS-CoV-2 patients is significantly deranged, with D-dimer, FDP, and FIB values significantly increased and AT levels significantly decreased. These findings support the notion that consumption coagulopathy, especially disseminated intravascular coagulation (DIC), may be common in SARS-CoV-2 patients and may negatively affect the clinical course. Routine monitoring of hemostasis tests may be useful for establishing an accurate therapeutic strategy and preventing disease progression. The study was approved by the Ethics Committee and Institutional Review Board of the Renmin Hospital of Wuhan University.